Burundi vs Netherlands (Kingdom of the): Proportion of the target population who received
Burundi
80.0%
in 2024
Netherlands (Kingdom of the)
81.0%
in 2024
Burundi rank
117th
Netherlands (Kingdom of the) rank
114th
Proportion of the target population who received over time
- Burundi
- Netherlands (Kingdom of the)
How they compare
Netherlands (Kingdom of the) currently reports 81.0% against 80.0% in Burundi, a difference of 1.0%.
Across all 12 years both countries report, Netherlands (Kingdom of the) has been ahead every year.
Burundi ranks 117th and Netherlands (Kingdom of the) ranks 114th of 193 countries.
Netherlands (Kingdom of the) has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burundi | Netherlands (Kingdom of the) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 68.6% | 91.0% | 22.4% | Netherlands (Kingdom of the) |
| 2020s | 82.6% | 85.2% | 2.6% | Netherlands (Kingdom of the) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received, Burundi or Netherlands (Kingdom of the)?
- Netherlands (Kingdom of the), at 81.0% against 80.0% in Burundi as of 2024.
- What is the difference in proportion of the target population who received between Burundi and Netherlands (Kingdom of the)?
- 1.0%, with Netherlands (Kingdom of the) ahead.
- How many years of comparable data are there for Burundi and Netherlands (Kingdom of the)?
- 12 years are reported by both, from 2013 to 2024.
- How do Burundi and Netherlands (Kingdom of the) rank globally for proportion of the target population who received?
- Burundi ranks 117th and Netherlands (Kingdom of the) ranks 114th of 193 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received measles-containing-vaccine second-dose (MCV2) (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.